Member Info for Propinquity

Morning Folks,

Was that a buy or a sell?

Chesh, I’m in stitches.

Ready yourselves for the Great North Runn.

Hmmm...when he talks about the company’ growing up, he means that he has to seek shareholders’ permission - in a grown-up manner - to dilute the company even more.

Futures, It’s winding up...

Less about incentivising shareholders, and more about desensitising them to dilutions.

Thanks for the responses, folks - a twelve-week wait for transferring my Calidus shares would be frightfully stressful; a less-stressful solution will be to open an account with, say, AJ Bell, and buy more - if you have the dosh.

Has anyone here successfully transferred Calidus shares from HL to another player like AJ Bell that deals directly on the ASX? If so, how easy is it?

If you have Carowner virus, you ought to get on contract the Covid-19 model

Markyess, Very kind of you to input and to calculate those figures during your free time - thanks. Well, your low-ball dividend-estimates certainly solidify the investment case for this company, allied with the recent directors’ buys - can’t wait for this time next year. Upside, upside, upside - with room to spare for more upside.

Or this board’s posters can Kerass you with information on this company ;-)

MK, It may well be that LSE has not updated its own info yet - I would doubt that their admission would have been delayed.

The 244 million-odd equity-raising shares should have been admitted for trading from 08.00 yesterday.

PMSL

DV, As I said when the copper price plummeted during the lockdown: focus on the mid- to long-term price, as miners do - not on short-term swings.

https://markets.businessinsider.com/commodities/copper-price

It’s the implication of applying for the next three years to further explore the mine that provokes suspicion amongst investors on where LR will obtain funds from to continue operating this company for that time - he has promulgated enough his non-dilutive funding-source(s), which he has to clarify.

Markyess, Agreed - a different conversation.

Anyway, any highly presumptive dividend calculations would be welcome to maintain this board’s posters’ convivial spirits.

Equity value of £605 million, equating to £3.60 a share - witness a steady climb towards that valuation:

https://www.proactiveinvestors.co.uk/companies/news/915478/amryt-pharma-well-capitalised-and-resilient-with-recurring-revenues-says-ceo-915478.html

Folks, But what is the ‘non-dilutive’ funding-source for the supposed next three years’ investigations - and for paying the staff? Has LR mined himself into a PR hole?